The NHS in England has approved a non-hormonal treatment for menopausal hot flushes and night sweats, according to the National Institute for Health and Care Excellence (NICE).
Veoza, also known as fezolinetant, is a daily pill that blocks nerve pathways in the brain that trigger symptoms. Around 500,000 women could benefit from the drug, particularly those who cannot use hormone replacement therapy (HRT) due to underlying health conditions.
Helen Knight, director of medicines evaluation at NICE, said: "For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be. The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost effective, offering value for the taxpayer."\
Treatment Availability
Veoza was approved in 2023 but has only now been recommended for treating moderate to severe symptoms of menopausal hot flushes and night sweats on the NHS. The decision applies in England, and Wales and Northern Ireland often follow the same NICE guidance.
Dr Sue Mann, national clinical director in women's health for NHS England, said symptoms of menopause including hot flushes and night sweats "can affect every part of a women's life". She welcomed the news, especially for women who are unable to take HRT or don't want to take it.
Eligibility and Restrictions
NICE said the drug is not recommended for women with breast cancer, other oestrogen-dependent cancers, or liver disease. Women who have had breast cancer in the past and have finished their treatment may be able to take it, but it would depend on their individual situation.
